Curis Inc share price logo

Curis Inc Share Price

NASDAQ: CRIS

Small Cap

$1.82

as on

Curis Inc Stock Performance

as on September 13, 2025 at 1:29 am IST

  • Day's Low

    Day's High

    $1.79
    $1.93
    downward going graph

    1.65%

    Downside

    6.04%

    Upside

    downward going graph

  • 52 Week's Low

    52 Week's High

    $1.02
    $6.44
    downward going graph

    43.96%

    Downside

    253.85%

    Upside

    downward going graph

Curis Inc share price movements today

Previous Close
$1.82
Open
$1.87
Volume
569.5K
Day's Low - High
$1.79 - $1.93
52 Week Low - High
$1.02 - $6.44

Curis Inc Historical Returns

1 Month Return
-0.55 %
3 Month Return
-25.71 %
1 Year Return
-66.67 %
3 Year Return
-89.99 %
5 Year Return
-91.88 %

Curis Inc Stock Fundamentals & Key Indicators

Check Curis Inc market cap, PE, PB, PEG ratios, dividend yield, and other key fundamental indicators.

Market Cap

$22.7M

EPS (TTM)

-2.59

Dividend Yield

0.00%

Quarterly Earnings Growth YOY

0.00%

PE Ratio (TTM)

-0.69

Industry PE ratio

-3.8535542168674697

P/B Ratio

0

PEG Ratio

0

EBITDA

-37.8M

Revenue (TTM)

11.4M

Profit Margin

0.00%

Return On Equity TTM

10139500.00%

Curis Inc Stock Valuation

Track how Curis Inc P/E has moved over time to understand its valuation trends.

Curis Inc in the last 5 years

  • Overview

  • Trends

Lowest (0.00x)

September 15, 2025

Industry (-3.85x)

September 15, 2025

Today (-0.69x)

September 15, 2025

Highest (-0.40x)

June 30, 2025

LowHigh

Today’s Price to Earnings Ratio: -0.69x

Curis Inc vs Peer Comparison

Compare market cap, revenue, PE, and other key metrics of Curis Inc with its industry peers.

Company
Analyst View
Market Cap
5 Years Return %PE RatioProfit Margin %
Curis Inc image
Curis Inc
BUY$22.7M-91.88%-0.690.00%
Alnylam Pharmaceuticals, Inc. image
Alnylam Pharmaceuticals, Inc.
BUY$61.1B280.5%-505.15-12.96%
Beone Medicines Ltd image
Beone Medicines Ltd
NA$37.7BNANA-3.89%
Vertex Pharmaceuticals Incorporated image
Vertex Pharmaceuticals Incorporated
BUY$101.2B54.04%28.0831.86%
Regeneron Pharmaceuticals, Inc. image
Regeneron Pharmaceuticals, Inc.
BUY$59.4B2.03%14.1131.37%

Stock Returns calculator for Curis Inc Stock including INR - Dollar returns

The Curis Inc stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.

*Dollar Return is the profit earned when the US dollar rises in value compared to the Indian rupee.

Investment Value

₹1,00,000

  • 1Y

  • 3Y

  • 5Y

  • 7Y

  • 10Y

Curis Inc investment value today

Current value as on today

₹38,472

Returns

₹61,528

(-61.53%)

Returns from Curis Inc Stock

₹66,667 (-66.67%)

Dollar Returns*

₹5,139 (+5.14%)

Analyst Recommendation on Curis Inc Stock

Based on 12 analysts

BUY

83.33%

Buy

16.67%

Hold

0.00%

Sell

Based on 12 analysts, 83.33% of analysts recommend a 'BUY' rating for Curis Inc. Average target price of $16.33

Curis Inc Share Price Target

Get share price movements and forecasts by analysts on Curis Inc.

What analysts predicted

88.85%UPSIDE

Target Price

$16.33

Current Price

$1.82

Analyzed by

12 Analysts

Target

$16.33

Curis Inc target price $16.33, a slight upside of 88.85% compared to current price of $1.82. According to 12 analysts rating.

Curis Inc Quarterly Profit & Loss

All numbers in Millions USD

Mar 2023
Jun 2023
Sep 2023
Dec 2023
Mar 2024
Jun 2024
Sep 2024
Dec 2024
Mar 2025
Jun 2025
Total Revenue
2
2
2
2
2
2
2
3
2
2
Gross Profit
2
2
2
2
1
2
2
3
2
2
Operating Income
-11
-12
-12
-12
-12
-12
-10
-8
-10
-8
EBITDA
-11
-12
-12
-11
-12
-12
-10
-8
-10
-8
Interest Expense
0
0
0
2
-
-
-
0
-
-
Depreciation
0
0
0
0
0
0
0
0
0
0
Income Before Tax
-11
-11
-12
-11
-11
-11
-10
-9
-10
-8
Income Tax Expense
0
0
0
0
0
-
-
-
-
-
Net Income
-11
-11
-12
-11
-11
-11
-10
-9
-10
-8
Net Profit Margin
-500.26%
-544.42%
-429.97%
-436.94%
-569.32%
-463.59%
-344.32%
-287.53%
-446.05%
-312.59%

Curis Inc Annual Profit & Loss

All numbers in Millions USD

Dec 2015
Dec 2016
Dec 2017
Dec 2018
Dec 2019
Dec 2020
Dec 2021
Dec 2022
Dec 2023
Dec 2024
Total Revenue
7
7
9
10
10
10
10
10
10
10
Gross Profit
7
7
9
9
9
10
10
9
10
10
Operating Income
-56
-58
-49
-29
-24
-24
-42
-53
-48
-44
EBITDA
-55
-57
-49
-28
-27
-24
-39
-52
-48
-42
Interest Expense
3
2
3
3
4
5
4
4
2
0
Depreciation
-
-
0
0
0
0
0
0
0
0
Income Before Tax
-58
-60
-53
-32
-32
-29
-45
-56
-47
-43
Income Tax Expense
3
2
3
0
4
4
5
3
0
-
Net Income
-58
-60
-53
-32
-36
-34
-50
-60
-47
-43
Net Profit Margin
-748.64%
-802.59%
-538.66%
-312.38%
-367.89%
-321.93%
-475.54%
-593.62%
-473.04%
-397.77%

Curis Inc Quarterly Cash Flow

All numbers in Millions USD

Jun 2023
Sep 2023
Dec 2023
Mar 2024
Jun 2024
Sep 2024
Dec 2024
Mar 2025
Jun 2025
Net Income
-11
-12
-11
-11
-11
-10
-9
-10
-8
Operating Cash Flow
-7
-8
-10
-13
-11
-5
-9
-7
-8
Investing Cash Flow
-3
0
14
18
-7
18
0
-
-
Financing Cash Flow
0
12
-2
-2
-1
-1
8
7
-2
Change in Cash
-11
4
2
3
-19
10
0
0
-10

Curis Inc Annual Cash Flow

All numbers in Millions USD

Dec 2016
Dec 2017
Dec 2018
Dec 2019
Dec 2020
Dec 2021
Dec 2022
Dec 2023
Dec 2024
Net Income
-60
-53
-32
-32
-29
-45
-56
-47
-43
Operating Cash Flow
-35
-48
-30
-26
-25
-37
-54
-38
-39
Investing Cash Flow
30
-3
21
-4
-49
-47
33
37
29
Financing Cash Flow
-1
64
-5
23
188
-4
0
7
3
Change in Cash
-7
12
-14
-7
114
-89
-20
6
-6

Global Institutional Holdings in Curis Inc

Funds
Holdings
Bleichroeder LP
8.63%
Armistice Capital, LLC
8.61%
Wealthquest Corporation
6.12%
Maverick Capital Ltd
5.26%
M28 Capital Management LP
4.34%
See all

Insights on Curis Inc

Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.

  • imgPOSITIVE IMPACT

    Revenue Rich

    img

    Revenue is up for the last 2 quarters, 2.38M → 2.74M (in $), with an average increase of 13.4% per quarter

  • imgPOSITIVE IMPACT

    Profit Spike

    img

    Netprofit is up for the last 2 quarters, -10.61M → -8.59M (in $), with an average increase of 23.5% per quarter

  • imgNO EFFECT

    Against Peers

    img

    In the last 1 year, Alnylam Pharmaceuticals, Inc. has given 75.6% return, outperforming this stock by 142.3%

  • imgNO EFFECT

    Against Peers

    img

    In the last 3 years, Alnylam Pharmaceuticals, Inc. has given 123.5% return, outperforming this stock by 213.5%

  • imgNEGATIVE IMPACT

    Price Dip

    img

    In the last 3 months, CRIS stock has moved down by -25.7%

About Curis Inc

curis is a publicly-traded biotechnology company (nasdaq: cris) focused on the development and commercialization of innovative drug candidates for the treatment of human cancers. curis’s pipeline of drug candidates includes cudc-907, which is currently being investigating in clinical trials in patients with relapsed or refractory diffuse large b-cell lymphoma with alterations in the myc oncogene. curis is also engaged in a broad collaboration with aurigene in the areas of immuno-oncology and precision oncology. as part of this collaboration, curis has exclusive licenses to oral small molecule antagonists of the pd1 and vista pathways, including pdl1/vista antagonist ca-170, and oral small molecule antagonists of the pd1 and tim3 pathways, including pdl1/tim3 antagonist ca-327, as well as to molecules designed to inhibit the irak4 kinase, including ca-4948. ca-170 is currently undergoing testing in a phase 1 trial in patients with advanced solid tumors and lymphomas. ca-4948 is currentl
OrganisationCuris Inc
HeadquartersBuilding C, Lexington, MA, United States, 02421
IndustryHealth Technology
CEOMr. James E. Dentzer
E-voting on sharesClick here to vote

Key Management of Curis Inc

Name

Title

Dr. Ahmed M. Hamdy M.D.

Chief Medical Officer

Mr. James E. Dentzer

President, CEO, Secretary, Treasurer & Director

Ms. Diantha Duvall CPA, M.B.A.

CFO and Principal Financial & Accounting Officer

Dr. Jonathan B. Zung Ph.D.

Chief Development Officer

Mr. Mark W. Noel

Vice President of Technology Management & Intellectual Property

Dr. Robert E. Martell M.D., Ph.D.

Chief Scientific Officer

Ms. Nancy Soohoo

VP & General Counsel

Ms. Rachel Blasbalg

Senior Director of Human Resources

FAQs

What is Curis Inc share price today?

Curis Inc share price today is $1.82 as on at the close of the market. Curis Inc share today touched a day high of $1.93 and a low of $1.79.

What is the 52 week high and 52 week low for Curis Inc share?

Curis Inc share touched a 52 week high of $6.44 on and a 52 week low of $1.02 on . Curis Inc stock price today i.e. is closed at $1.82,which is 71.74% down from its 52 week high and 78.43% up from its 52 week low.

What is Curis Inc's market capitalisation today?

Curis Inc market capitalisation is $0.00T as on .

How to invest in Curis Inc Stock (CRIS) from India?

  1. Step 1: Open a free US stocks account on INDmoney App and transfer your Rupees into Dollars to your INDmoney US stocks account. For a step by step instruction, check How to Transfer Money to Your US Stocks Account .
  2. Step 2: Search for Curis Inc on INDmoney app. Click on Buy button. You can invest as low as $1.5 in Curis Inc Shares that will get you 0.8242 shares as per Curis Inc share price of $1.82 per share as on September 13, 2025 at 1:29 am IST.

What is the minimum amount required to buy Curis Inc Stock (CRIS) from India?

Indian investors can start investing in Curis Inc (CRIS) shares with as little as ₹88.27 or $1 (as of ) using the INDmoney app.
For example: If you want to invest $10 or ₹882.70 in Curis Inc stock (as per the Rupee-Dollar exchange rate as on ). Based on Curis Inc share’s latest price of $1.82 as on September 13, 2025 at 1:29 am IST, you will get 5.4945 shares of Curis Inc. Learn more about fractional shares .

What are the returns that Curis Inc has given to Indian investors in the last 5 years?

Curis Inc stock has given -91.88% share price returns and 20.01% dollar appreciation to an Indian investor in the last 5 years.
Read more about How do Currency Exchange Rates impact your returns on US Stock Investments?